Document Type

Report

Publication Date

12-20-2022

Comments

This article is the author's final published version in Diabetes Technology and Therapeutics, Volume 25, Issue 2, 2023, Pg. 143 - 147.

The published version is available at https://doi.org/10.1089/dia.2022.0323. Copyright © Jasmin R. Kastner, et al., 2023; Published by Mary Ann Liebert, Inc.

Abstract

Insulin exposure varies over 3 days of insulin infusion set (IIS) wear making day-to-day insulin dosing challenging for people with diabetes (PWD). Here we report insulin pharmacodynamic (PD) and pharmacokinetic (PK) data extending these observations to 7 days of IIS wear. PWD (A1C ≤8.5%, C-peptide tmax (P < 0.001), Cmax (P < 0.05), and mean residence time (P < 0.0001). Area under the insulin concentration curve (AUC0–300) declined by ∼24% from days 0 to 7 (P < 0.05). These results confirm/extend previous observations showing progressive acceleration of insulin exposure over IIS wear time. This may have implications for PWD and designers of closed-loop algorithms, although larger studies are necessary to confirm this. The study was registered in clinicaltrials.gov (NCT04398030).

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

36342853

Language

English

Share

COinS